Loading...
XSHE002007
Market cap3.94bUSD
Jan 13, Last price  
15.58CNY
1D
-1.33%
1Q
-2.07%
Jan 2017
-56.42%
Name

Hualan Biological Engineering Inc

Chart & Performance

D1W1MN
XSHE:002007 chart
P/E
19.49
P/S
5.40
EPS
0.80
Div Yield, %
0.00%
Shrs. gr., 5y
0.12%
Rev. gr., 5y
10.68%
Revenues
5.34b
+18.26%
320,787,821361,277,009352,991,929351,137,848475,162,7981,220,493,4291,261,620,656961,395,932972,460,2151,117,611,9991,243,487,9611,471,763,3081,934,669,6632,368,176,5693,216,898,7223,699,941,9905,023,206,2634,436,200,1254,516,979,4085,341,872,557
Net income
1.48b
+37.66%
41,358,25852,542,88779,001,163120,429,390187,258,195608,475,487612,360,499370,719,279299,787,871475,337,495538,417,396589,118,927780,312,519820,823,4711,139,512,9361,283,449,0491,613,105,2621,298,897,1641,076,265,2831,481,578,849
CFO
1.35b
+40.59%
21,479,23098,240,132131,429,335179,015,279161,175,908607,725,451609,531,570335,928,539494,692,263510,700,233497,148,698548,622,932329,938,357177,417,5221,292,636,1431,362,760,2811,325,292,9791,432,495,972957,311,9071,345,838,781
Dividend
Jun 14, 20240.3 CNY/sh
Earnings
Mar 28, 2025

Profile

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.
URL
https://www.hualanbio.com/
IPO date
Jun 25, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,341,873
18.26%
4,516,979
1.82%
Cost of revenue
3,122,766
2,820,365
Unusual Expense (Income)
NOPBT
2,219,107
1,696,615
NOPBT Margin
41.54%
37.56%
Operating Taxes
315,958
180,765
Tax Rate
14.24%
10.65%
NOPAT
1,903,149
1,515,850
Net income
1,481,579
37.66%
1,076,265
-17.14%
Dividends
(364,873)
Dividend yield
0.88%
Proceeds from repurchase of equity
(1)
BB yield
0.00%
Debt
Debt current
1,000,350
800,819
Long-term debt
18,297
318,594
Deferred revenue
54,370
Other long-term liabilities
51,178
1
Net debt
(5,362,683)
(2,348,557)
Cash flow
Cash from operating activities
1,345,839
957,312
CAPEX
(753,411)
Cash from investing activities
(1,038,150)
Cash from financing activities
(454,955)
1,917,966
FCF
(130,187)
396,049
Balance
Cash
3,108,593
3,467,970
Long term investments
3,272,736
Excess cash
6,114,236
3,242,121
Stockholders' equity
11,176,840
12,182,344
Invested Capital
8,367,624
10,097,141
ROIC
20.61%
17.82%
ROCE
15.28%
12.70%
EV
Common stock shares outstanding
1,824,380
1,825,106
Price
22.13
-2.21%
22.63
-22.34%
Market cap
40,373,526
-2.25%
41,302,159
-22.59%
EV
37,072,595
40,765,622
EBITDA
2,492,895
1,969,431
EV/EBITDA
14.87
20.70
Interest
13,457
30,266
Interest/NOPBT
0.61%
1.78%